Study details
Enrolling now
WU-CART-007 Trial
Wugen, Inc.
NCT IDNCT06514794ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
125
Study length
about 3.9 years
Ages
1+
Locations
8 sites in CA, FL, MO +4
Why this study is shown
Matches lymphomaActively enrollingPHASE2
What this study is about
This trial is testing WU-CART-007, a new treatment for T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. The goal is to see if WU-CART-007 can help patients achieve a complete response with no detectable cancer cells remaining.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive WU-CART-007
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cell therapy
Endpoints
Primary: MRD Pos Cohort - Response Rate, R/R Cohort - Composite Complete Response Rate
Body systems
Oncology